Who
Gregory R. Friberg
EVP, Chief R&D Officer
Company insider
Files Form 4 as: EVP, Chief R&D Officer, BioMarin Pharmaceutical.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $1.1M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Sep 2024
- Last trade
- 30 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Feb – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 1 Oct 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $245K4,086 at $60.00 | filing |
| 7 May 2026filed 11 May 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $177K3,281 at $53.85 | filing |
| 7 May 2026filed 11 May 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $177K3,281 at $53.85 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $91K1,629 at $56.05 | filing |
| 17 Mar 2026filed 18 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $91K1,629 at $56.05 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —19,150 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —45,600 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —45,600 at $0.00 | filing |
| 16 Mar 2026filed 18 Mar 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —19,150 at $0.00 | filing |
| 26 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $382K6,326 at $60.38 | filing |
| 26 Feb 2026filed 26 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $382K6,326 at $60.38 | filing |
| 31 Oct 2025filed 13 Feb 2026 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | $18K398 at $45.54 | filing |
| 30 Sep 2025filed 2 Oct 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $179K3,304 at $54.16 | filing |
| 17 Mar 2025filed 18 Mar 2025 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —41,170 at $0.00 | filing |
| 17 Mar 2025filed 18 Mar 2025 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —17,750 at $0.00 | filing |
| 30 Sep 2024filed 1 Oct 2024 | BMRN BioMarin Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code A | —49,850 at $0.00 | filing |
| 30 Sep 2024filed 1 Oct 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —21,190 at $0.00 | filing |
| 30 Sep 2024filed 1 Oct 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —7,870 at $0.00 | filing |
News
Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)BMRN · tickerreport.com · 18 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by UBS GroupBMRN · tickerreport.com · 17 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Barclays Analyst SaysBMRN · themarketsdaily.com · 14 Oct 2026
0 headlines in the last 90 days name Gregory R. Friberg; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.